Drugs / C-TCR055
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04368182 | Apr → Aug 2020 | hepatocellular carcinoma | Zhejiang University | Unknown | No outcome recorded |
| Phase 1 | NCT03971747 | Aug 2019 → Jun 2020 | hepatocellular carcinoma | Shanghai AbelZeta Ltd. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | C-TCR055 | “AFP Specific T Cell Receptor Transduced T Cells Injection(C-TCR055) in Unresectable Hepatocellular Carcinoma” NCT03971747 ↗ |
| Modality | Cell therapy | “Autologous T cells transduced with lentivirus” NCT03971747 ↗ |
| Route | Intravenous | “Autologous C-TCR055 administered by intravenous (IV) infusion” NCT03971747 ↗ |
| Target | AFP | “Autologous T cells transduced with lentivirus encoding AFP specific TCR gene” NCT03971747 ↗ |